Overview

Pyrukynd is a medicine used to treat adults with pyruvate kinase deficiency (PKD), an inherited disease that causes red blood cells to break down faster than normal.

PKD is rare, and Pyrukynd was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 22 April 2020. Further information on the orphan designation can be found here: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2270.

Pyrukynd contains the active substance mitapivat.

Pyrukynd can only be obtained with a prescription. It is available as tablets to be taken by mouth. The recommended starting dose is one 5 mg tablet taken twice a day. The dose can be increased every four weeks, based on the patient’s haemoglobin (the protein in red blood cells that carries oxygen around the body) levels and their need for a transfusion in the previous 8 weeks. The maximum recommended dose of Pyrukynd is 50 mg twice a day.

If treatment needs to be interrupted or stopped completely, the dose of Pyrukynd should be gradually reduced over a period of 1 to 2 weeks.

For more information about using Pyrukynd, see the package leaflet or contact your doctor or pharmacist.

Patients with PKD have a defective form of pyruvate kinase, a protein in red blood cells which converts glucose into energy. As a result, their red blood cells cannot make enough energy to hold their shape, causing them to break down before the body has time to replace them. This excessive breakdown of red blood cells is known as haemolytic anaemia.

The active substance in Pyrukynd, mitapivat, attaches to and activates pyruvate kinase, causing it to work more effectively and thereby preventing the red blood cells of these patients from being broken down too fast.

The benefits of Pyrukynd were evaluated in two main studies. In the first study, involving 80 patients with PKD who were not regularly receiving blood transfusions, Pyrukynd was compared with placebo (dummy treatment). In this study, 40% of patients treated with Pyrukynd had an increase of their haemoglobin levels of 1.5 g/dL, which was maintained at 2 or more check-ups carried out after 16, 20 and 24 weeks of treatment, compared with none of the patients treated with placebo.

In the second study, involving 27 patients who were regularly receiving blood transfusions, Pyrukynd was not compared with placebo or any other medicines. In this study, the volume of red blood cells received in transfusions was reduced by more than a third in 37% of patients.

The most common side effects with Pyrukynd (which may affect more than 1 in 10 people) are insomnia (difficulty sleeping), nausea (feeling sick) and decreased levels of the hormone oestrone seen in blood tests in male patients.

For the full list of side effects and restrictions of Pyrukynd, see the package leaflet.

There are limited treatment options for patients with PKD as management of the disease is restricted to supportive treatments to improve the symptoms and complications associated with haemolytic anaemia. Although there were some limitations associated with the main studies, Pyrukynd has been shown to provide clinically meaningful benefits to some patients with PKD, by increasing haemoglobin levels and reducing the need for transfusions. It was therefore considered that Pyrukynd addressed an unmet medical need in these patients.

Furthermore, the side effects of Pyrukynd are considered manageable. The European Medicines Agency therefore decided that Pyrukynd’s benefits are greater than its risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pyrukynd have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Pyrukynd are continuously monitored. Suspected side effects reported with Pyrukynd are carefully evaluated and any necessary action taken to protect patients.

Pyrukynd received a marketing authorisation valid throughout the EU on 9 November 2022.

български (BG) (146.51 KB - PDF)

View

español (ES) (121.95 KB - PDF)

View

čeština (CS) (141.93 KB - PDF)

View

dansk (DA) (108.06 KB - PDF)

View

Deutsch (DE) (124.28 KB - PDF)

View

eesti keel (ET) (109.94 KB - PDF)

View

ελληνικά (EL) (146.36 KB - PDF)

View

français (FR) (123.44 KB - PDF)

View

hrvatski (HR) (144.17 KB - PDF)

View

italiano (IT) (120.32 KB - PDF)

View

latviešu valoda (LV) (159.4 KB - PDF)

View

lietuvių kalba (LT) (143.42 KB - PDF)

View

magyar (HU) (144.5 KB - PDF)

View

Malti (MT) (144.87 KB - PDF)

View

Nederlands (NL) (121.63 KB - PDF)

View

polski (PL) (134.39 KB - PDF)

View

português (PT) (123.13 KB - PDF)

View

română (RO) (141.88 KB - PDF)

View

slovenčina (SK) (141.81 KB - PDF)

View

slovenščina (SL) (141.22 KB - PDF)

View

Suomi (FI) (118.72 KB - PDF)

View

svenska (SV) (120.35 KB - PDF)

View

Product information

български (BG) (919.19 KB - PDF)

View

español (ES) (792.43 KB - PDF)

View

čeština (CS) (850.23 KB - PDF)

View

dansk (DA) (809.01 KB - PDF)

View

Deutsch (DE) (456.23 KB - PDF)

View

eesti keel (ET) (802.53 KB - PDF)

View

ελληνικά (EL) (912.82 KB - PDF)

View

français (FR) (808.77 KB - PDF)

View

hrvatski (HR) (887.09 KB - PDF)

View

íslenska (IS) (811.25 KB - PDF)

View

Gaeilge (GA) (806.5 KB - PDF)

View

italiano (IT) (795.85 KB - PDF)

View

latviešu valoda (LV) (855.7 KB - PDF)

View

lietuvių kalba (LT) (840.8 KB - PDF)

View

magyar (HU) (902.63 KB - PDF)

View

Malti (MT) (914.02 KB - PDF)

View

Nederlands (NL) (817.63 KB - PDF)

View

norsk (NO) (778.33 KB - PDF)

View

polski (PL) (884.61 KB - PDF)

View

português (PT) (816.52 KB - PDF)

View

română (RO) (887.19 KB - PDF)

View

slovenčina (SK) (882.63 KB - PDF)

View

slovenščina (SL) (877.56 KB - PDF)

View

Suomi (FI) (445.51 KB - PDF)

View

svenska (SV) (801.51 KB - PDF)

View

icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (50.17 KB - PDF)

View

español (ES) (40.86 KB - PDF)

View

čeština (CS) (45.67 KB - PDF)

View

dansk (DA) (41.82 KB - PDF)

View

Deutsch (DE) (42.37 KB - PDF)

View

eesti keel (ET) (41.96 KB - PDF)

View

ελληνικά (EL) (46.92 KB - PDF)

View

français (FR) (42.75 KB - PDF)

View

hrvatski (HR) (43.55 KB - PDF)

View

íslenska (IS) (42.49 KB - PDF)

View

Gaeilge (GA) (40.85 KB - PDF)

View

italiano (IT) (17.41 KB - PDF)

View

latviešu valoda (LV) (44.59 KB - PDF)

View

lietuvių kalba (LT) (44.87 KB - PDF)

View

magyar (HU) (45.83 KB - PDF)

View

Malti (MT) (45.72 KB - PDF)

View

Nederlands (NL) (41.6 KB - PDF)

View

norsk (NO) (41.18 KB - PDF)

View

polski (PL) (43.93 KB - PDF)

View

português (PT) (41.78 KB - PDF)

View

română (RO) (44.93 KB - PDF)

View

slovenčina (SK) (46.15 KB - PDF)

View

slovenščina (SL) (43 KB - PDF)

View

Suomi (FI) (39.71 KB - PDF)

View

svenska (SV) (41.65 KB - PDF)

View

Product details

Name of medicine
Pyrukynd
Active substance
mitapivat sulfate
International non-proprietary name (INN) or common name
mitapivat
Therapeutic area (MeSH)
  • Genetic Diseases, Inborn
  • Anemia, Hemolytic
Anatomical therapeutic chemical (ATC) code
B06AX04

Pharmacotherapeutic group

Other hematological agents

Therapeutic indication

Pyrukynd is indicated for the treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (see section 4.4).

Authorisation details

EMA product number
EMEA/H/C/005540

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Marketing authorisation holder
Agios Netherlands B.V.

Zuidplein 36
1077XV Amsterdam
Netherlands

Opinion adopted
15/09/2022
Marketing authorisation issued
09/11/2022

Assessment history

This page was last updated on

Share this page